Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CPH NASDAQ:CRON TSE:GUD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHCipher PharmaceuticalsC$16.90-1.3%C$16.91C$11.98▼C$20.56C$429.11M1.15370627,075 shs17,900 shsCRONCronos Group$2.75$2.73$1.92▼$3.43$1.03B0.89854,565 shs566,992 shsGUDKnight TherapeuticsC$9.80C$8.95C$5.66▼C$10.17C$962.16M-0.20678899,645 shs74,352 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHCipher Pharmaceuticals-1.34%-1.97%+3.62%-13.20%+30.80%CRONCronos Group0.00%-0.36%+2.61%+7.00%+31.58%GUDKnight Therapeutics0.00%-1.90%+3.38%+29.29%+59.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHCipher PharmaceuticalsC$16.90-1.3%C$16.91C$11.98▼C$20.56C$429.11M1.15370627,075 shs17,900 shsCRONCronos Group$2.75$2.73$1.92▼$3.43$1.03B0.89854,565 shs566,992 shsGUDKnight TherapeuticsC$9.80C$8.95C$5.66▼C$10.17C$962.16M-0.20678899,645 shs74,352 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHCipher Pharmaceuticals-1.34%-1.97%+3.62%-13.20%+30.80%CRONCronos Group0.00%-0.36%+2.61%+7.00%+31.58%GUDKnight Therapeutics0.00%-1.90%+3.38%+29.29%+59.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHCipher Pharmaceuticals 2.00HoldC$17.000.59% UpsideCRONCronos Group 2.20Hold$2.30-16.36% DownsideGUDKnight Therapeutics 3.00BuyC$9.50-3.06% DownsideCurrent Analyst Ratings BreakdownLatest CPH, CRON, and GUD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026CRONCronos Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/12/2026CRONCronos Group TD SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/12/2026CPHCipher Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHoldC$17.005/8/2026GUDKnight Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuyC$9.50(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHCipher PharmaceuticalsC$50.94M8.42C$4.79 per share3.53C$5.25 per share3.22CRONCronos Group$146.59M7.00$0.01 per share219.35$3.00 per share0.92GUDKnight TherapeuticsC$510.45M1.88C$2.55 per share3.85C$8.00 per share1.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHCipher PharmaceuticalsC$11.41MC$1.1914.20N/AN/A60.82%25.69%7.90%N/ACRONCronos Group-$9.45M$0.01275.28N/AN/A-1.14%-1.26%-1.20%8/6/2026 (Estimated)GUDKnight Therapeutics-C$30.73MC$0.06163.33N/A1.10%0.73%0.51%N/ALatest CPH, CRON, and GUD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026CRONCronos Group$0.01N/AN/AN/A$44.20 millionN/A5/11/2026Q1 2026CRONCronos Group$0.01$0.01N/A$0.04$42.20 million$45.21 million5/7/2026Q1 2026CPHCipher PharmaceuticalsN/AC$0.33N/AC$0.33N/AC$17.39 million5/7/2026Q1 2026GUDKnight TherapeuticsN/AC$0.13N/AC$0.13N/AC$147.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPHCipher PharmaceuticalsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHCipher Pharmaceuticals0.321.252.67CRONCronos GroupN/A21.8720.73GUDKnight Therapeutics8.862.321.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHCipher Pharmaceuticals2.29%CRONCronos Group8.71%GUDKnight Therapeutics22.99%Insider OwnershipCompanyInsider OwnershipCPHCipher Pharmaceuticals42.00%CRONCronos Group7.80%GUDKnight Therapeutics45.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHCipher Pharmaceuticals525.39 millionN/ANot OptionableCRONCronos Group450373.03 million343.94 millionOptionableGUDKnight Therapeutics72598.18 millionN/ANot OptionableCPH, CRON, and GUD HeadlinesRecent News About These CompaniesThis analyst just upped his price target on Knight TherapeuticsMay 8, 2026 | cantechletter.comCKnight Therapeutics Inc. (GUD:CA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comKnight to Present at the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | markets.businessinsider.comTSX Value Picks Knight Therapeutics And 2 Other Stocks Estimated Below Intrinsic ValueMarch 25, 2026 | uk.finance.yahoo.comThis analyst just raised his price target on Knight TherapeuticsMarch 22, 2026 | cantechletter.comCKnight Therapeutics advances chronic GvHD expansion strategyFebruary 27, 2026 | finance.yahoo.com3 TSX Growth Companies With Insider Ownership As High As 27%January 28, 2026 | finance.yahoo.comProfound Medical Regains Exclusive Distribution Rights for TULSA-PRO(R) in Canada from KnightNovember 12, 2025 | barrons.comKnight Therapeutics Closes $100MM Revolving Credit FacilityNovember 3, 2025 | abladvisor.comAKnight Therapeutics Secures US$100 Million Credit Facility to Boost GrowthOctober 31, 2025 | msn.comKnight Therapeutics announces approval, launch of MINJUVI in ArgentinaOctober 30, 2025 | msn.comKnight Therapeutics Announces Filing of New Drug Submission for CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in CanadaJuly 18, 2025 | finanznachrichten.deKnight Therapeutics gains rights to Sumitomo Pharma products in CanadaJune 9, 2025 | thepharmaletter.comTIs Knight Therapeutics stock a buy?June 5, 2025 | cantechletter.comCEarnings call transcript: Knight Therapeutics Q1 2025 beats EPS forecastMay 10, 2025 | uk.investing.comKnight Therapeutics is a buy, Stifel saysMay 9, 2025 | cantechletter.comCWhy this value manager likes Knight Therapeutics but is changing the channel on Warner Bros. DiscoveryMarch 28, 2025 | theglobeandmail.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 2,500,000 SharesMarch 25, 2025 | insidertrades.comCollective, Knight at 52-Week Highs on NewsMarch 21, 2025 | baystreet.caSime Armoyan selling more Knight Therapeutics (GUD)March 20, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026Apple Just Handed These 4 Memory Stocks Their Best News of the YearBy Bridget Bennett | June 28, 2026Is the Memory Rally Still Alive After the Semiconductor Sell-Off?By Jessica Mitacek | July 2, 2026Micron’s HBM Surge Could Redefine the AI Growth StoryBy Thomas Hughes | June 25, 2026CPH, CRON, and GUD Company DescriptionsCipher Pharmaceuticals TSE:CPHC$16.90 -0.23 (-1.34%) As of 07/13/2026 04:00 PM EasternCipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.Cronos Group NASDAQ:CRON$2.75 0.00 (0.00%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$2.74 -0.02 (-0.55%) As of 07/13/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Knight Therapeutics TSE:GUDC$9.80 0.00 (0.00%) As of 07/13/2026 04:00 PM EasternKnight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
